EP4333979A4 - Procédé de titrage de doses d'agents psychédéliques - Google Patents

Procédé de titrage de doses d'agents psychédéliques

Info

Publication number: EP4333979A4
Authority: EP; European Patent Office
Prior art keywords: psychedelics; titration; dose; methods
Prior art date: 2021-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP22799340.9A

Other languages

German (de)

English (en)

Other versions

EP4333979A1 (fr

Inventor

Robert Barrow

Daniel R. Karlin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mind Medicine Inc

Original Assignee

Mind Medicine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-05-03

Filing date

2022-05-01

Publication date

2025-01-15

2022-05-01 Application filed by Mind Medicine Inc filed Critical Mind Medicine Inc

2024-03-13 Publication of EP4333979A1 publication Critical patent/EP4333979A1/fr

2025-01-15 Publication of EP4333979A4 publication Critical patent/EP4333979A4/fr

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Dental Preparations (AREA)
Measurement Of Radiation (AREA)

EP22799340.9A 2021-05-03 2022-05-01 Procédé de titrage de doses d'agents psychédéliques Pending EP4333979A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202163183579P	2021-05-03	2021-05-03
PCT/US2022/027179 WO2022235529A1 (fr)	2021-05-03	2022-05-01	Procédé de titrage de doses d'agents psychédéliques

Publications (2)

Publication Number	Publication Date
EP4333979A1 EP4333979A1 (fr)	2024-03-13
EP4333979A4 true EP4333979A4 (fr)	2025-01-15

Family

ID=83932279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22799340.9A Pending EP4333979A4 (fr)	2021-05-03	2022-05-01	Procédé de titrage de doses d'agents psychédéliques

Country Status (7)

Country	Link
EP (1)	EP4333979A4 (fr)
JP (1)	JP2024517194A (fr)
AU (2)	AU2022268891A1 (fr)
CA (1)	CA3216939A1 (fr)
IL (1)	IL308068A (fr)
TW (1)	TW202245767A (fr)
WO (1)	WO2022235529A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3182156A1 (fr)	2020-05-08	2021-11-11	Psilera Inc.	Nouvelles compositions de matiere et compositions pharmaceutiques
US12378194B2 (en)	2021-05-25	2025-08-05	Atai Therapeutics, Inc.	N, n-dimethyltryptamine salts and crystalline salt forms
WO2022261383A1 (fr)	2021-06-09	2022-12-15	ATAI Life Sciences AG	Nouveaux promédicaments et conjugués de diméthyltryptamine
JP2024531437A (ja)	2021-08-20	2024-08-29	ファーマラバイオテックインコーポレイテッド	（ｒ）－３，４－メチレンジオキシメタンフェタミン及び（ｓ）－３，４－メチレンジオキシメタンフェタミン又は（ｒ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミン及び（ｓ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用
CA3238440A1 (fr)	2021-12-30	2023-07-06	Atai Therapeutics, Inc.	Analogues de dimethyltryptamine utilises en tant que medicaments d'administration d'oxyde nitrique
EP4486448A1 (fr)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-cristaux ou sels comprenant de la psilocine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170157343A1 (en) *	2014-06-30	2017-06-08	Syqe Medical Ltd.	Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (fr) *	2019-01-30	2020-08-06	Diamond Therapeutics Inc.	Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
WO2020169850A1 (fr) *	2019-02-22	2020-08-27	Gh Research Limited	5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA50786A (fr) *	2017-10-26	2022-04-27	Blumentech S L	Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2021003467A1 (fr) *	2019-07-04	2021-01-07	Sw Holdings, Inc.	Compositions de dosage et procédés d'utilisation de composés psychédéliques

2022
- 2022-05-01 IL IL308068A patent/IL308068A/en unknown
- 2022-05-01 AU AU2022268891A patent/AU2022268891A1/en not_active Abandoned
- 2022-05-01 JP JP2023566881A patent/JP2024517194A/ja active Pending
- 2022-05-01 WO PCT/US2022/027179 patent/WO2022235529A1/fr not_active Ceased
- 2022-05-01 EP EP22799340.9A patent/EP4333979A4/fr active Pending
- 2022-05-01 CA CA3216939A patent/CA3216939A1/fr active Pending
- 2022-05-03 TW TW111116665A patent/TW202245767A/zh unknown
2025
- 2025-08-12 AU AU2025217270A patent/AU2025217270A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170157343A1 (en) *	2014-06-30	2017-06-08	Syqe Medical Ltd.	Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (fr) *	2019-01-30	2020-08-06	Diamond Therapeutics Inc.	Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
WO2020169850A1 (fr) *	2019-02-22	2020-08-27	Gh Research Limited	5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "How to Microdose: A Step by Step Guide - Microdosing information, research, community, coaching and more.", 30 April 2021 (2021-04-30), pages 1 - 9, XP093230199, Retrieved from the Internet <URL:https://web.archive.org/web/20210430131601/https://microdosinginstitute.com/how-to/how-to-microdose/> *
KUYPERS KIM P.C.: "The therapeutic potential of microdosing psychedelics in depression", vol. 10, 27 August 2020 (2020-08-27), XP093229382, ISSN: 2045-1253, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/2045125320950567> DOI: 10.1177/2045125320950567 *
See also references of WO2022235529A1 *

Also Published As

Publication number	Publication date
AU2022268891A1 (en)	2023-11-09
EP4333979A1 (fr)	2024-03-13
TW202245767A (zh)	2022-12-01
JP2024517194A (ja)	2024-04-19
CA3216939A1 (fr)	2022-11-10
AU2025217270A1 (en)	2025-08-28
WO2022235529A1 (fr)	2022-11-10
IL308068A (en)	2023-12-01

Publication	Publication Date	Title
EP4333979A4 (fr)	2025-01-15	Procédé de titrage de doses d'agents psychédéliques
EP4069212A4 (fr)	2024-03-06	Inhibiteurs de hif-2 alpha
EP3605228A4 (fr)	2021-01-06	Composition sensible aux rayonnements et procédé de formation de motif de réserve
EP3750334A4 (fr)	2021-11-10	Procédé d'amélioration de la localisation d'un son surround
EP3277276A4 (fr)	2019-02-06	Procédés d'administration d'inhibiteurs de glutaminase
EP3538494A4 (fr)	2020-07-15	Procédé de traitement électrochimique de l'eau
EP3540433A4 (fr)	2020-08-19	Système permettant d'estimer la concentration d'un agent d'injection dans le sol
EP3893883A4 (fr)	2022-09-07	Méthodes pour le traitement de la dépression
EP3752161A4 (fr)	2021-12-22	Méthodes de traitement de la fibrose
EP3897582C0 (fr)	2024-09-11	Procédé de séchage par pulvérisation de semaglutide
EP3941921A4 (fr)	2023-05-03	Méthodes thérapeutiques de traitement de l'hépatite b
EP4227290C0 (fr)	2024-05-22	Procédé de recyclage de dmf
EP3578161A4 (fr)	2020-12-23	Méthode d'amélioration de la stabilité au stockage d'un produit cosmétique
EP3583521A4 (fr)	2020-08-12	Exécution d'ordres de parts fractionnelles
EP3804504A4 (fr)	2021-07-21	Procédé d'amélioration d'absorption d'engrais
EP3426632A4 (fr)	2020-02-26	Inhibiteurs de l'interaction creb-cbp pour le traitement de la leucémie
EP4395815A4 (fr)	2025-07-30	Procédé d'amélioration de la stabilité d'inhibiteurs du point de contrôle immunitaire
EP3833752A4 (fr)	2022-06-01	Procédé de traitement de la mucopolysaccharidose de type ii
EP3756133A4 (fr)	2021-11-17	Procédé d'authentification d'articles
EP3786904C0 (fr)	2025-02-26	Méthode d'évulation télématique des composants d'un véhicule
EP3816298A4 (fr)	2022-03-16	Procédé permettant l'évaluation de la cytotoxicité d'un gaz
EP3761207C0 (fr)	2023-08-30	Procédé de fiabilisation de contenus d'opérations de chaîne de blocs
DE112019002959A5 (de)	2021-04-08	Verfahren zur Detektion von Kennleuchten
EP3600550A4 (fr)	2020-08-26	Procédés de traitement d'un mélanome
EP3551347A4 (fr)	2020-08-12	Procédés de passivation d'adhésifs

Legal Events

Date	Code	Title	Description
2022-11-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-12-05	TPAA	Information related to observations by third parties modified	Free format text: ORIGINAL CODE: EPIDOSCTIPA
2023-12-05	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2024-02-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2024-02-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-03-13	17P	Request for examination filed	Effective date: 20231130
2024-03-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-08-07	DAV	Request for validation of the european patent (deleted)
2024-08-07	DAX	Request for extension of the european patent (deleted)
2024-12-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0025000000 Ipc: A61K0031137000
2025-01-15	A4	Supplementary search report drawn up and despatched	Effective date: 20241216
2025-01-15	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/00 20060101ALI20241210BHEP Ipc: A61K 31/675 20060101ALI20241210BHEP Ipc: A61K 31/48 20060101ALI20241210BHEP Ipc: A61K 31/4045 20060101ALI20241210BHEP Ipc: A61K 31/137 20060101AFI20241210BHEP
2025-09-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-10-22	17Q	First examination report despatched	Effective date: 20250919